top of page

Resultados de la búsqueda

Search results for "silence therapeutics"

59 results found for "silence therapeutics"

  • Webinar: Silence Therapeutics and Their Work with MPNs

    The Global MPN Scientific Foundation is pleased to host a special webinar introducing Silence Therapeutics Date: May 20th, 2025 Time: 6:00 PM – 7:00 PM (CEST) About Silence Therapeutics Silence Therapeutics is Silence Therapeutics collaborates globally to drive forward science that can make a real impact on patient I have been in the pharmaceutical industry for 25 years helping mostly small companies like Silence Therapeutics The webinar will cover: An overview of Silence Therapeutics’ scientific approach and platform Their current

  • Video | A New Possible Treatment for PV with Silence Therapeutics

    On May 20th, 2025, the Global MPN Scientific Foundation hosted a webinar featuring Silence Therapeutics

  • Videos | Webinar: New Treatment for PV with Prof. Susanne Isfort and Silence Therapeutics

    Therapeutics. Content guide* Part 1: Silence Therapeutics and a Promising New Treatment for PV * Watch More on MPN World Part 1: Silence Therapeutics and a Promising New Treatment for PVIn the first part, Alberto Martinez  explained the science behind divesiran, a therapy currently in development for PV, and how Silence Therapeutics Full video: Part 1: Silence Therapeutics and a Promising New Treatment for Polycythemia Vera (Part 2)

  • New Polycythemia Vera Research: Inside the Divesiran Clinical Trial with Silence Therapeutics

    As part of the educational collaboration between the Global MPN Scientific Foundation and Silence Therapeutics This third session of the webinar series brings together experts from Silence Therapeutics who will share Curtis Rambaran, Chief Medical Officer, Silence Therapeutics 🎤 Speaker: Joe Loiars, Senior Director Curtis Rambaran will introduce the structure and research strategy of Silence Therapeutics and explain In the second part of the webinar, Joe Loiars will provide an overview of Silence Therapeutics’ activities

  • New Polycythemia Vera Research: Watch the Webinar on the Divesiran Clinical Trial with Silence Therapeutics

    This webinar explores the divesiran clinical trial, developed by Silence Therapeutics, and provides an reliable information can help patients, caregivers, and healthcare professionals better understand how new therapeutic In this webinar, experts from Silence Therapeutics present key aspects of the divesiran clinical trial to expanding knowledge about polycythemia vera and help researchers better understand how different therapeutic

  • Webinar: Clinical Trials, PV and the Future. A Live Conversation with Dr. Susanne Isfort and Silence Therapeutics

    Following the success of our first webinar with Silence Therapeutics, we are excited to announce the This time, we continue on Silence Therapeutics and their investigational therapy for Polycythemia Vera * About Silence Therapeutics * Webinar Details * Register now What to Expect? Therapeutics)He will continue explaining divesiran, a treatment in development for PV, and explain how About Silence TherapeuticsSilence Therapeutics is a UK-based biotech company developing precision RNA-based

  • Divesiran in Polycythemia Vera: What the Phase 2 SANRECO Results Tell Us

    Our webinar with Alberto Martínez from Silence Therapeutics is now available. Webinar: SANRECO Phase 2 Results in Polycythemia Vera | Silence Therapeutics ▶️ Watch the full webinar According to the results announced by Silence Therapeutics, a clinical response was achieved by: 88% Both schedules showed activity on the primary endpoint, and Silence Therapeutics has stated that its The next step: Phase 3According to Silence Therapeutics, the next stage of development will be a Phase

  • Webinar: Latest Updates from the Divesiran Clinical Trial for Patients with Polycythemia Vera

    A Global MPN session with Alberto Martínez, Senior Director of Clinical Science at Silence Therapeutics (CET) and will feature Alberto Martínez, Senior Director of Clinical Science at Silence Therapeutics. (CET) Format: Online Speaker: Alberto Martínez Position: Senior Director of Clinical Science, Silence Therapeutics Topic: Latest updates from the Phase 2 Divesiran clinical trial for PV patients.

  • Clinical Trials in MPNs 2026

    ongoing research in polycythemia vera (PV), with a focus on the divesiran clinical trial developed by Silence Therapeutics. This session offers an accessible overview of innovative therapeutic approaches currently being studied WEBINAR I NEW RESEARCH: INSIDE THE DISVESIRAN CLINICAL TRIAL FOR PV WITH SILENCE THERAPEUTICS Latest Comprehensive Cancer Center (United States), shares key updates on the trial, including its design, therapeutic

  • Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

    Takeda and Protagonist Therapeutics, Inc., today announced the signing of a worldwide license and collaboration Patel, Ph.D., President and CEO of Protagonist Therapeutics.

  • Season’s Greetings from the Global MPN Family

    We also hosted and supported webinars on ongoing clinical trials, including sessions with: * Silence Therapeutics * Geron Among the highlights were our MPN Educational Roundtables, addressing often-taboo

  • One MPN Family: YouTube Videos, Summary & Highlights from the 5th MPN Spring Symposium

    The first presentation was given by Alberto Martínez, Senior Director of Clinical Science at Silence Therapeutics, who shared insights on RNA based approaches in MPNs and how patient-reported outcomes are integrated into development strategies. 5th Spring Symposium Barcelona 2025 - Disvesiran Clinical trial Silence Therapeutics and Q&A The second talk was led by Carmelo Alonso, Director, Global Medical Oncology, Myeloid

bottom of page